Skip to main content

Beneficial ownership — 13D / 13G

87,314 recent Schedule 13D / 13G filings — activist (13D) and passive (13G) stakes above 5% of a class.

Reporting person Issuer Schedule % of class Filed
Dr. Ehud Geller PRFX PRF Technologies Ltd. 13G/A 19.85% 2y
Merck Healthcare KGaA, Darmstadt Germany an affiliate of Merck KGaA, Darmstadt, Germany MLTX MoonLake Immunotherapeutics 13G/A 4.7% 2y
Marco Ferri MKTW Marketwise, Inc. 13G 6.7% 2y
PURA VIDA INVESTMENTS, LLC LYRA Lyra Therapeutics, Inc. 13G/A 3.06% 2y
TEACHERS INSURANCE & ANNUITY ASSOCIATION OF AMERICA NCDL Nuveen Churchill Direct Lending Corp. 13G/A 12.42% 2y
Zdravka Medarova RNAZ Transcode Therapeutics, Inc. 13G/A 0.4% 2y
Amber Mason MKTW Marketwise, Inc. 13G 9.1% 2y
BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC HERZ Herzfeld Credit Income Fund, Inc 13G 12.4% 2y
Christy Lovig AVNI Arvana Inc 13G 5.56% 2y
Kerri Ann Hulet AVNI Arvana Inc 13G/A 5.56% 2y
Charles Youakim SEZL Sezzle Inc. 13D 43.6% 2y
PERCEPTIVE ADVISORS LLC LYRA Lyra Therapeutics, Inc. 13D/A 24.3% 2y
Luxor Capital Group, LP TFIN Triumph Financial, Inc. 13G/A 5.2% 2y
Jason Kelly DNA Ginkgo Bioworks Holdings, Inc. 13D/A 5% 2y
Edward W. Cochran CFBK Cf Bankshares Inc. 13D/A 6.5% 2y
TTWFGP LLC WLKP Westlake Chemical Partners LP 13D/A 44.1% 2y
Umbrella Global Energy S.A. TURB Turbo Energy, S.A. 13D 90.96% 2y
5AM Ventures VI, L.P. VOR Vor Biopharma Inc. 13D/A 9.4% 2y
Reshma P. Shetty DNA Ginkgo Bioworks Holdings, Inc. 13D/A 10.5% 2y
Thomas W. Powell POWL Powell Industries Inc 13D/A 20.5% 2y
Gayle G. Green GRC Gorman Rupp Co 13D 9.6% 2y
Goal Acquisitions Sponsor LLC PUCK Goal Acquisitions Corp. Common Stock 13D/A 54.48% 2y
Jeffrey S. Gorman GRC Gorman Rupp Co 13D 10.5% 2y
StepStone Group LP NEUE NeueHealth, Inc. 13D/A 6.8% 2y
Value Base Ltd. VLN Valens Semiconductor Ltd. 13G/A 10.07% 2y
JANE STREET GROUP, LLC CVNA Carvana Co. 13G/A 3.8% 2y
Jill Foss Watson CACC Credit Acceptance Corp 13D/A 15.1% 2y
Robert L. Dumont IDR Idaho Strategic Resources, Inc. 13G 4.38% 2y
Notch View Capital Management, LLC FREE Whole Earth Brands, Inc. Class A Common Stock 13D/A 0% 2y
Rubric Capital Management LP XPER Xperi Inc. 13D/A 8.6% 2y
Monte M. Brem STEP StepStone Group Inc. 13D/A 49.1% 2y
BFI Co., LLC PAHC Phibro Animal Health Corp 13D/A 49.9% 2y
The Column Group III, LP TNYA Tenaya Therapeutics, Inc. 13D/A 17.7% 2y
RA CAPITAL MANAGEMENT, L.P. HOWL Werewolf Therapeutics, Inc. 13D/A 15.2% 2y
Family Trading Inc. TOPS Top Ships Inc. 13D/A 63.35% 2y
Charles Ashton Newhall STEP StepStone Group Inc. 13D/A 5.3% 2y
Michael Graves EGRX Eagle Pharmaceuticals, Inc. 13D 1.8% 2y
VERIZON COMMUNICATIONS INC BMR Beamr Imaging Ltd. 13G 0% 2y
Saba Capital Management, L.P. STHO Star Holdings 13G 5.2% 2y
Van Herk Investments B.V. PRQR ProQR Therapeutics N.V. 13G/A 10.1% 2y
Peter Hebert EVLV Evolv Technologies Holdings, Inc. 13D/A 1.1% 2y
SPRING CREEK CAPITAL LLC ALCYF Alchemy Investments Acquisition Corp 1 13G 5.42% 2y
Fung Ching Wong LSBWF LakeShore Biopharma Co., Ltd. 13D 0.23% 2y
Bain Capital Life Sciences Opportunities III, LP KYTX Kyverna Therapeutics, Inc. 13G 7.4% 2y
Oxus Capital PTE. LTD. BRLS Borealis Foods Inc. 13D 46.3% 2y
Reza Soltanzadeh BRLS Borealis Foods Inc. 13D 17.12% 2y
Barthelemy Helg BRLS Borealis Foods Inc. 13D 14.99% 2y
Fennell Todd W. PRTA Prothena Corp Public Ltd Co 13G 5.85% 2y
MILLENNIUM MANAGEMENT LLC ACRS Aclaris Therapeutics, Inc. 13G 5.3% 2y
SCULLY WILLIAM P PRTA Prothena Corp Public Ltd Co 13G 6.53% 2y